Arcturus Therapeutics Holdings Inc.
NASDAQ:ARCTBiotechnology
+$0.15 today
- Market cap
- $229.72M
- Beta
- 2.35
- P/E (TTM)
- -2.7
- EPS (TTM)
- -$2.77
Volume 0.45M
Average 0.43M
Returns on capital
Arcturus Therapeutics Holdings Inc. management
Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.
Return Metrics
ROE, ROIC & ROA over time
ROE
-30.7%
avg -50.2%
ROIC
-31.4%
avg -34.8%
ROA
-24.3%
avg -26.9%
Analysis
ROA is currently the strongest return metric at -24.3% versus its period average of -26.9%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Leadership
Who runs the company?
Review the executive team, tenure, compensation, and ownership.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|
Joseph E. Payne | Founder, President, Chief Executive Officer & Director | USD 750K | 54 | 175.00K | 0.62% |
Padmanabh Chivukula | Founder, Chief Scientific Officer, Chief Operating Officer & Secretary | USD 572K | 47 | — | — |
Lance Kurata | Chief Legal Officer | USD 540K | — | 54.00K | 0.19% |
Joseph Roberts | Principal Accounting Officer & Controller | USD 219.58K | 43 | 10.00K | 0.04% |
Igor Smolenov | Chief Development Officer | — | — | — | — |
Ye Zhang | Chief Regulatory & Quality Assurance Officer | — | — | — | — |
Dennis Mulroy | Chief Financial Officer | — | 71 | 0 | <0.01% |
Kevin T. Skol | Chief Business Officer | — | — | — | — |
Natash O. Bowman | Chief Human Resources Officer | — | — | — | — |
Neda Safarzadeh | Vice President and Head of IR/PR & Marketing | — | — | — | — |
Compensation is shown in the reported currency; data updated Nov 7, 2026.
Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding May 1, 2026.
Insider trading
Are insiders buying or selling?
Follow recent insider purchases and sales reported on Form 4.
Insider Trading
SEC Form 4 transactions — last 12 months
No open-market purchases or sales in the last 12 months.
Growth analysis
Is management growing the business?
Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A5 analysts |
| Revenue | N/A | N/A | -31.1% | +37.7% (5yr)5 analysts |
| Net Income | N/A | N/A | N/A | N/A5 analysts |
| EBIT | N/A | N/A | N/A | N/A5 analysts |
Analysis
Recent growth has been strongest in Revenue at -31.1% over three years. Forward estimates point to Revenue at +37.7% (5yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Who does Arcturus Therapeutics Holdings Inc. compete with?
Open similar companies to compare how their management teams allocate capital.
Questions
Management questions
Common questions about ARCT's management, answered from reported figures.
Who manages ARCT?
Arcturus Therapeutics Holdings Inc. (ARCT) lists 10 active executives. The top listed executive is Igor Smolenov, Chief Development Officer.
Are ARCT insiders buying or selling?
Recent insider activity shows net selling of $31.60M.
Continue the stock analysis
Jump to another research area for this company.